Wockhardt gets US FDA nod to enter the $2.6 billion Norvasc market

Wockhardt Ltd says it is set to launch amlodipine tablets in the US market. Wockhardt will sell the drug in tablets of 2.5 mg, 5 mg and 10 mg amlodipine besylate, which is used for treating hypertension and other related cardiac ailments.

Amlodipine is the generic name for the brand Norvasc, sold in the US by Pfizer. According to the IMS, the US market for Amlodipine tablets is about $2.6 billion equivalent to 1.7 billion tablets.

"Wockhardt is gaining a very strong position in several other cardiovascular products, like Enalapril and Captopril," said the Habil Khorakiwala, Chairman, Wockhardt. "With amlodipine, it will reinforce our robust cardiovascular portfolio. This rapid increase in our US product portfolio is enabling us to synergistically gain market share across products," he added.

The amlodipine tablets are manufactured at the US FDA-certified formulation plant at Waluj in Maharashtra.